Opthea (OPT) Competitors $3.41 +0.23 (+7.23%) As of 07/3/2025 02:20 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. NAMS, DNLI, KNSA, RXRX, APGE, CGON, AGIO, INDV, IRON, and BLTEShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Indivior (INDV), Disc Medicine (IRON), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Apogee Therapeutics CG Oncology Agios Pharmaceuticals Indivior Disc Medicine Belite Bio NewAmsterdam Pharma (NASDAQ:NAMS) and Opthea (NASDAQ:OPT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation. Does the media refer more to NAMS or OPT? In the previous week, Opthea had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for Opthea and 2 mentions for NewAmsterdam Pharma. Opthea's average media sentiment score of 0.92 beat NewAmsterdam Pharma's score of 0.00 indicating that Opthea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opthea 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, NAMS or OPT? NewAmsterdam Pharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Which has preferable valuation and earnings, NAMS or OPT? Opthea has lower revenue, but higher earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M47.95-$241.60M-$1.88-10.35Opthea$120K4,373.61-$220.24MN/AN/A Do institutionals and insiders believe in NAMS or OPT? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 3.2% of Opthea shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate NAMS or OPT? NewAmsterdam Pharma presently has a consensus price target of $42.89, indicating a potential upside of 120.40%. Opthea has a consensus price target of $1.33, indicating a potential downside of 60.90%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Is NAMS or OPT more profitable? Opthea has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -397.45%. Opthea's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-397.45% -37.34% -33.45% Opthea N/A N/A N/A SummaryOpthea beats NewAmsterdam Pharma on 9 of the 15 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.84M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.01%P/E RatioN/A7.5519.3119.89Price / Sales4,373.61284.29424.59117.07Price / CashN/A41.7026.2128.59Price / Book-6.097.397.925.55Net Income-$220.24M-$55.04M$3.17B$248.49M7 Day PerformanceN/A3.01%2.18%5.37%1 Month PerformanceN/A-0.21%1.25%6.63%1 Year Performance80.42%4.48%33.90%21.20% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.369 of 5 stars$3.41+7.2%$1.33-60.9%+80.4%$524.84M$120K0.008Gap UpNAMSNewAmsterdam Pharma2.2491 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.08B$45.56M-9.634Positive NewsAnalyst UpgradeDNLIDenali Therapeutics4.5157 of 5 stars$13.99-0.8%$33.71+141.0%-30.5%$2.05B$330.53M-5.24430News CoverageKNSAKiniksa Pharmaceuticals International3.4031 of 5 stars$27.67-1.3%$38.80+40.2%+43.9%$2.05B$423.24M-110.68220Analyst UpgradeRXRXRecursion Pharmaceuticals1.7434 of 5 stars$5.06+0.6%$7.00+38.3%-28.1%$2.04B$58.84M-2.86400APGEApogee Therapeutics2.8981 of 5 stars$43.43+0.1%$94.60+117.8%+25.1%$2.00BN/A-12.0691Trending NewsAnalyst ForecastOptions VolumeHigh Trading VolumeCGONCG Oncology2.3239 of 5 stars$26.00+0.2%$58.67+125.6%-15.6%$1.98B$1.14M-17.2261Gap DownAGIOAgios Pharmaceuticals3.9594 of 5 stars$33.26-0.6%$58.60+76.2%-15.5%$1.94B$36.50M2.96390INDVIndivior2.0111 of 5 stars$14.74+5.7%$17.00+15.3%+6.5%$1.92B$1.19B-47.551,051High Trading VolumeIRONDisc Medicine2.9856 of 5 stars$52.96-2.8%$96.70+82.6%+17.4%$1.89BN/A-13.5130BLTEBelite Bio2.4367 of 5 stars$57.70-2.3%$96.67+67.5%+31.3%$1.88BN/A-42.4310 Related Companies and Tools Related Companies NAMS Alternatives DNLI Alternatives KNSA Alternatives RXRX Alternatives APGE Alternatives CGON Alternatives AGIO Alternatives INDV Alternatives IRON Alternatives BLTE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPT Stock Alerts